A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue OncoImmunology Année : 2017

A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment

Résumé

Despite approval for the treatment of various malignancies, clinical application of cytokines such as type I interferon (IFN) is severely impeded by their systemic toxicity. AcTakines (Activity-on-Target cytokines) are optimized immunocytokines that, when injected in mice, only reveal their activity upon cell-specific impact. We here show that type I IFN-derived AcTaferon targeted to the tumor displays strong antitumor activity without any associated toxicity, in contrast with wild type IFN. Treatment with CD20-targeted AcTaferon of CD20+ lymphoma tumors or melanoma tumors engineered to be CD20+, drastically reduced tumor growth. This antitumor effect was completely lost in IFNAR- or Batf3-deficient mice, and depended on IFN signaling in conventional dendritic cells. Also the presence of, but not the IFN signaling in, CD8+ T lymphocytes was critical for proficient antitumor effects. When combined with immunogenic chemotherapy, low-dose TNF, or immune checkpoint blockade strategies such as anti-PDL1, anti-CTLA4 or anti-LAG3, complete tumor regressions and subsequent immunity (memory) were observed, still without any concomitant morbidity, again in sharp contrast with wild type IFN. Interestingly, the combination therapy of tumor-targeted AcTaferon with checkpoint inhibiting antibodies indicated its ability to convert nonresponding tumors into responders. Collectively, our findings demonstrate that AcTaferon targeted to tumor-specific surface markers may provide a safe and generic addition to cancer (immuno)therapies.
Fichier principal
Vignette du fichier
ms_Oncoimmunol.pdf (313.19 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-02322002 , version 1 (24-10-2019)

Identifiants

Citer

Anje Cauwels, Sandra van Lint, Geneviève Garcin, Jennyfer Bultinck, Franciane Paul, et al.. A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment. OncoImmunology, 2017, 7 (3), pp.e1398876. ⟨10.1080/2162402X.2017.1398876⟩. ⟨hal-02322002⟩
58 Consultations
97 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More